<DOC>
	<DOC>NCT02135705</DOC>
	<brief_summary>This global product exposure registry is a multicentre, long-term, prospective, observational cohort study (exposure registry), designed to evaluate the long term safety and effectiveness of lomitapide.</brief_summary>
	<brief_title>LOWER: Lomitapide Observational Worldwide Evaluation Registry</brief_title>
	<detailed_description>To evaluate the occurrence of adverse events of special interest, long term effectiveness of lomitapide, and to evaluate whether prescribers of lomitapide are following screening and monitoring recommendations as specified in product labeling.</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Hyperlipoproteinemia Type II</mesh_term>
	<criteria>Adult patients (age â‰¥18 years) who meet one of the following two criteria: Initiating treatment with lomitapide at the time of registry enrolment, or initiated treatment with lomitapide within 15 months prior to enrolment into the registry and after lomitapide commercial availability in the country. Patients who have the ability to understand the requirements of the study and provide written informed consent to comply with the study data collection procedures. Patients who are receiving lomitapide in clinical trials Patients receiving an investigational agent, defined as any drug or biologic agent other than lomitapide that has not received MA in the country of participation.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>